High-dose therapy and immunomodulatory drugs in multiple myeloma

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 17, 2002, Pages 26-33

  Barlogie, Bart ^a   Shaughnessy, John ^a   Zangari, Maurizio ^a   Tricot, Guido ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ENDOTHELIAL RECEPTOR INHIBITOR; ENOXAPARIN; ETOPOSIDE; FLUDARABINE; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 6 ANTIBODY; LACTATE DEHYDROGENASE; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RECEPTOR BLOCKING AGENT; THALIDOMIDE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE; WARFARIN;

ALLOGRAFT; ARTICLE; AUTOGRAFT; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CHROMOSOME 13; CHROMOSOME ABERRATION; CLINICAL TRIAL; CYTOGENETICS; DEEP VEIN THROMBOSIS; DRUG CHOICE; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; MULTIPLE MYELOMA; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SURVIVAL RATE;

EID: 0037252480     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.34074     Document Type: Article

References (25)

1. Barlogie B: Advances in therapy of multiple myeloma: Lessons from acute leukemia. Clin Cancer Res 3:2605-2613, 1997
2. Barlogie B, Jagannath S, Desikan R, et al: Total Therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55-65, 1999
3. Desikan R, Barlogie B, Sawyer J, et al: Results of high dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95:4008-4010, 2000
4. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
5. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494, 2001
6. Barlogie B, Zangari M, Spencer T, et al: Thalidomide in the management of multiple myeloma. Semin Hematol 38:250-259, 2001
7. Neben K, Moehler TM, Benner A, et al: Dose-dependent effect of thalidomide on overall survival in relapsed and refractory multiple myeloma. Blood 98:690, 2001 (abstr)
8. Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group. N Engl J Med 334:488-493, 1996
9. Berenson JR, Lichtenstein A, Porter L, et al: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events: Myeloma Aredia Study Group. J Clin Oncol 16:593-602, 1998
10. Dhodapkar M, Singh J, Mehta J, et al: Anti-myeloma activity of pamidronate in vivo. Br J Haematol 103:530-532, 1998
11. Yaccoby S, Pearse RN, Johnson CL, et al: Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116:278-290, 2002
12. Yaccoby S, Johnson CL, Mahaffey C, et al: Thalidomide metabolism and its anti-myeloma activity efficacy in vivo. Blood 94:317a, 1999 (abstr 1416)
13. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-4950, 2000
14. Zangari M, Tricot G, Zeldis J, et al: Results of phase I study of CC-5013 for the treatment of multiple myeloma patients who relapse after high dose chemotherapy. Blood 98:3226a, 2001 (abstr)
15. Shaughnessy J, Barlogie B, McCoy J, et al: Early relapse after Total Therapy II for multiple myeloma is significantly associated with cytogenetic abnormalities of chromosome 13 but not interphase FISH-del 13 or plasma cell labeling index. Blood 11:3060a, 2001 (abstr)
16. Barlogie, B, McCoy J, Shaughnessy J, et al: Total Therapy II for newly diagnosed multiple myeloma: preliminary data on feasibility and efficacy in the first 231 enrolled patients: Comparison with predecessor trial Total Therapy I. Blood 98:2857a, 2001 (abstr)
17. Zangari M, Anaissie E, Barlogie B, et al: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614-1615, 2001
18. Tricot G, Siegel E, Langmaid C, et al: Angiochemotherapy for multiple myeloma with DT-PACE results in a high response rate but in contrast to tandem transplants with melphalan does not affect durable disease control. Blood 98:3531a, 2001 (abstr)
19. Zangari M, Siegel E, Anaissie E, et al: Risk factors for deep vein thrombosis in a large group of myeloma patients treated with thalidomide: The Arkansas experience. Blood 98:681a, 2001 (abstr)
20. Tricot G, Vesole DH, Jagannath S, et al: Graft-versus-myeloma effect: Proof of principle. Blood 87:1196-1198, 1996
21. Feinstein L, Sandmaier B, Maloney D, et al: Nonmyeloablative allogeneic transplantation as a treatment for relapsed hematologic malignancy after a failed conventional autologous or allogeneic transplant. Blood 98:3550a, 2001 (abstr)
22. Badros A, Barlogie B, Morris C, et al: High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 97:2574-2579, 2001
23. Badros A, Barlogie B, Siegel E, et al: Improved outcome of allogeneic transplantation in non-myeloablative multiple myeloma. J Clin Oncol 20:1295-1303, 2002
24. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
25. Zhan F, Hardin J, Bumm K, et al: Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells. Blood 99:1745-1757, 2002